Search

everythinglearnresearchcommunity

for

Search:↓

A new, efficient method has been developed to detect darolutamide and thalidomide, drugs used for certain hair loss and prostate cancer treatments, in pharmaceuticals and body fluids.

Drugs targeting the Androgen Receptor are effective for treating prostate cancer and other androgen-related conditions.

ADT, especially enzalutamide, may increase the risk of heart rhythm problems and sudden death in men.

Proxalutamide significantly lowered hospital admissions for male COVID-19 patients compared to a placebo.

Proxalutamide significantly lowered hospitalization rates in women with mild-to-moderate COVID-19.

Adding dutasteride to therapy may improve treatment for advanced salivary duct cancer.

Androgen-deprivation therapies increase the risk of certain heart conditions, but testosterone treatment may help.

Proxalutamide helps COVID-19 patients get rid of the virus faster and recover quicker.

Gemcitabine and Disitamab Vedotin effectively and safely reduced bladder cancer in a patient.

Disitamab vedotin and gemcitabine effectively treated bladder cancer without major side effects.

Early diagnosis and individualized treatment improve outcomes for Congenital Adrenal Hyperplasia.

Men's sensitivity to male hormones might affect how severe COVID-19 gets for them.

Blocking the virus's entry into cells by targeting certain pathways could lead to early COVID-19 treatments.

Sex hormones may affect COVID-19 severity, with men often faring worse, and targeting related pathways could offer treatment options.

New androgen receptor modulators show promise for treating diseases like prostate cancer and muscle wasting.

The androgen receptor is a promising target for breast cancer treatment, especially in triple-negative cases, but more research is needed for personalized therapies.

COVID-19 may worsen with androgens; anti-androgen drugs could help.

Balancing testosterone may reduce COVID-19 severity.

Extracellular vesicles and androgen receptors may help identify prostate cancer resistance and reduce SARS-CoV-2 infection.

Proxalutamide improved recovery, lowered death rates, and reduced hospital stay for COVID-19 patients.

Completing a 14-day proxalutamide treatment significantly lowers death rates in hospitalized COVID-19 patients.

The new delivery method for dutasteride is more effective and has fewer side effects.

Testosterone with dutasteride improves muscle strength and body composition in trans men.

The trial will test if proxalutamide is safe and effective in reducing death in severe COVID-19 patients.

The nanocrystalline suspension effectively delivers dutasteride over time with minimal inflammation.

Dutasteride effectively treats enlarged prostate with manageable side effects.